Cornea/External Disease News

The FDA granted orphan drug designation for Cellusion’s CLS001, a corneal endothelial cell substitute for bullous keratopathy, according to a press release.

The office-based thermal eyelid treatment TearCare significantly improved tear breakup time and measures of meibomian gland secretion compared with Restasis in patients with dry eye disease, according to 6-month trial data.

Throughout the year, Healio publishes a host of blogs on topics ranging from common conditions like keratoconus and glaucoma to crossover care that includes concussion management and diseases of the brain.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Ashvin Agarwal, MD, overviews his video on traumatic iridodialysis repair.

Nordic Pharma has acquired Visant Medical through its subsidiary Amring Pharmaceuticals.

Azura Ophthalmics announced positive topline results from its phase 2 study of AZR-MD-001 in patients with contact lens discomfort and signs of meibomian gland dysfunction.

Oculis has announced the first patient first visit in its phase 2b RELIEF trial evaluating licaminlimab, the company’s novel anti-tumor necrosis factor-alpha biologic eye drop, for treatment of moderate to severe dry eye disease.

A group of researchers found an association between keratoconus and connective tissue hyperlaxity in a large cohort of adolescents and young adults.

Tarsus Pharmaceuticals has announced positive topline results from the Ersa phase 2a trial evaluating TP-03 for treatment of meibomian gland disease in patients with Demodex mites, with significant improvements reported in two key measures.

We are fortunate today that not only are there new and better forms of corneal transplants, but we also do not have to refer keratoconus patients for a transplant nearly as often.